Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

BACKGROUND Pneumonia and bloodstream infections (BSI) due to extensively drugresistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenemresistant Enterobacterales (CRE) are associated with high mortality rates, and therapeutic options remain limited.This trial assessed whether combination therapy with colistin and meropenem was superior to colistin monotherapy for the treatment of these infections. METHODSThe OVERCOME (Colistin Monotherapy versus Combination Therapy) trial was an international, randomized, double-blind, placebo-controlled trial.We randomly assigned participants to receive colistin (5 mg/kg once followed by 1.67 mg/kg every 8 hours) in combination with either meropenem (1000 mg every 8 hours) or matching placebo for the treatment of pneumonia and/or BSI caused by XDR A. baumannii, XDR P. aeruginosa, or CRE.The primary outcome was 28-day mortality, and secondary outcomes included clinical failure and microbiologic cure. RESULTSBetween 2012 and 2020, a total of 464 participants were randomly assigned to treatment, and 423 eligible patients comprised the modified intention-to-treat population.A. baumannii was the predominant trial pathogen (78%) and pneumonia the most common index infection (70%).Most patients were in the intensive care unit at the time of enrollment (69%).There was no difference in mortality (43 vs. 37%; P50.17), clinical failure (65 vs. 58%; difference, 6.8 percentage points; 95% confidence interval [CI], 23.1 to 16.6), microbiologic cure (65 vs. 60%; difference, 4.8 percentage points; 95% CI, 25.6 to 15.2), or adverse events (acute kidney injury, 52 vs. 49% [P50.55];hypersensitivity reaction, 1 vs. 3% [P50.22]; and neurotoxicity, 5 vs. 2% [P50.29]) between patients receiving monotherapy and combination therapy, respectively.